Clinical trials · Massachusetts
Non Small Cell Lung Cancer clinical trials in Massachusetts
We’re tracking 130 recruiting non small cell lung cancer studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT07458347RecruitingPhase 1
Study of a new drug for advanced solid tumors with a KRAS mutation
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
Boston, MassachusettsAges 18 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Boston, MassachusettsAges 18 years+ - NCT07149363RecruitingPhase 2
Chemo and immunotherapy after surgery for small cell lung cancer
This trial tests whether adding immunotherapy (durvalumab) to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. It is for people who have had their cancer completely removed and are well enough to start treatment soon after surgery.
Boston, MassachusettsAges 18 years+ - NCT07843940RecruitingPhase 1/Phase 2
Two study drugs for extensive-stage small cell lung cancer
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
Boston, MassachusettsAges 18 years+ - NCT04787042RecruitingPhase 1/Phase 2
Safety and early benefits of ST-067 for advanced solid tumors
This early-stage trial tests ST-067 to see if it is safe and whether it may shrink advanced cancers. It also looks at how the drug moves through the body and affects the immune system.
Boston, MassachusettsAges 18 years+ - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07600801Recruiting
Lung Cancer Screening for People With Family History
This study looks at how to best screen people for lung cancer who have close relatives with a history of lung cancer. Researchers will use existing CT chest scans (imaging tests) to see if screening can help catch lung cancer early in high-risk families.
Boston, MassachusettsAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Boston, MassachusettsAges 18 years+ - NCT07491497RecruitingPhase 1/Phase 2
TRI-611 for ALK-positive lung cancer
This study tests an experimental pill for people with a specific type of lung cancer. The trial will see if the drug is safe and if it helps shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT07412041Recruiting
Exercise program for stage II-III lung cancer before surgery
This study tests a personalized exercise program for people with stage II or III non-small cell lung cancer who are about to start cancer treatment before surgery. The goal is to see if exercise can help prepare your body for treatment and recovery.
Boston, MassachusettsAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Boston, MassachusettsAges 18 years+ - NCT07405190RecruitingPhase 2
Ivonescimab with or without chemo for advanced NSCLC
This study tests a new drug, ivonescimab, alone or with chemotherapy (carboplatin and pemetrexed), for people with advanced lung cancer that has specific gene changes and has already been treated with targeted therapy. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Boston, MassachusettsAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
Boston, MassachusettsAges 18 years+ - NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT07291037RecruitingPhase 3
Comparing a new drug to standard chemo for advanced lung cancer
This trial tests a new drug called datopotamab deruxtecan against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has already been treated. The new drug targets a protein called TROP2 found on cancer cells, which may help slow or stop the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
Boston, MassachusettsAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Boston, MassachusettsAges 18 years+ - NCT07154706RecruitingPhase 3
Taletrectinib vs placebo after surgery for ROS1-positive lung cancer
This trial tests whether taletrectinib (a targeted pill) can help prevent lung cancer from coming back after surgery in people whose tumors have a ROS1 gene change. You would take either taletrectinib or a placebo (inactive pill) for about a year after surgery.
Boston, MassachusettsAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Worcester, MassachusettsAges 18 years+ - NCT07132190RecruitingPhase 2
Radiation for growing brain tumors with same-day planning
This study tests whether a precise, one-day radiation treatment for brain tumors that are growing or in tricky spots can be effective with a smaller safety margin. It's designed for people whose brain tumors are changing quickly or sitting near areas of swelling or recent surgery.
Boston, MassachusettsAges 18 years+ - NCT07130786RecruitingPhase 2
Preventing seizures with medication for brain tumors in movement area
This study tests whether giving a seizure medication (levetiracetam) to people with brain tumors in the movement area can prevent seizures. It compares taking the medication to not taking it, starting before any seizure occurs.
Boston, MassachusettsAges 18 years+
Non Small Cell Lung Cancer trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting non small cell lung cancer studies listed above.
- Massachusetts General Hospital · 9 studies
- Dana-Farber Cancer Institute · 7 studies
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Brigham and Women's Hospital / Dana-Farber Cancer Institute
- Dana Farber Cancer Center
- Dana-Farber/Massachusetts General Hospital, Inc
- Local Institution - 0603
What taking part in a non small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Non Small Cell Lung Cancer trials in other states
Common questions
- Are there non small cell lung cancer clinical trials in Massachusetts?
- Yes. We're currently tracking 130 recruiting non small cell lung cancer studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non small cell lung cancer study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non small cell lung cancer studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.